Exhibit 99.1

April 06, 2006 01:47 PM US Eastern Timezone

Biomet Press Release

WARSAW, Ind.--(BUSINESS WIRE)--April 6, 2006--Biomet, Inc. (NASDAQ:BMET)
confirmed today that Morgan Stanley & Co. Incorporated is assisting it in
exploring strategic alternatives focused on enhancing shareholder value. The
Company stated that no decisions have been made and there is no assurance that
this exploration will result in any specific action. Daniel P. Hann, interim
President and Chief Executive Officer, said, "We believe that this review is a
prudent exercise and is consistent with management's commitment to our
shareholders and Team Members."

The Company also stated that it does not expect to disclose developments with
respect to its exploration of alternatives unless required.

Biomet, Inc. and its subsidiaries design, manufacture and market products used
primarily by musculoskeletal medical specialists in both surgical and
non-surgical therapy. The Company's product portfolio encompasses
reconstructive products, including orthopedic joint replacement devices, bone
cements and accessories, and dental reconstructive implants; fixation
products, including electrical bone growth stimulators, internal and external
orthopedic fixation devices, craniomaxillofacial implants and bone substitute
materials; spinal products, including spinal stimulation devices, spinal
hardware and orthobiologics; and other products, such as arthroscopy products
and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet
and its subsidiaries currently distribute products in more than 100 countries.

For further information contact Greg W. Sasso, Vice President, Corporate
Development and Communications at (574) 372-1528 or Barbara Goslee, Manager,
Corporate Communications at (574) 372-1514.

This press release contains certain statements that are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934, as amended. Although
the Company believes that the assumptions, on which the forward-looking
statements contained herein are based, are reasonable, any of those
assumptions could prove to be inaccurate given the inherent uncertainties as
to the occurrence or non-occurrence of future events. There can be no
assurance that the forward-looking statements contained in this press release
will prove to be accurate. The inclusion of a forward-looking statement herein
should not be regarded as a representation by the Company that the Company's
objectives will be achieved.

All of Biomet's financial information may be obtained on our website at
www.biomet.com or you may contact us by e-mail at
investor.relations@biometmail.com.